AnaptysBio Inc

ANABNASDAQ · USD
45.61USD0.00 (-0.27%)
349

AnaptysBio Inc (ANAB) Historical Volatility

ANAB's 30 day historical volatility is 48.86%, in the 30th percentile of readings over the past year. This is an average percentile, meaning AnaptysBio Inc shares have moved roughly in line with their typical range. ANAB's 30 day implied volatility sits at 103.35%, with an IV Rank of 90.87%, leaving IV 54.49 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 17, 2026.

Read more

Tracking ANAB historical volatility helps you see how much AnaptysBio Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ANAB's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ANAB 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ANAB's 30 day historical volatility, or ANAB HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ANAB's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

Historical Volatility

HV Percentile
30thHV Percentile
Moderate

Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.

Historical Volatility (30d)48.86%

HV Percentile30th

Implied Volatility (30d)103.35%

IV Rank90.87%

IV Minus HV+54.49%

As of Nov 17, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 17, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 17, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →